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Four monoclonal antibodies have been raised against voltage-sensitive Ca2+ channel dihydropyridine re- 
ceptors from rabbit skeletal muscle. When tested by immunoblot assay of denatured transverse tubule mem- 
branes in reducing polyacrylamide g ls, each recognised a single polypeptide of M, - 140000 that co-migrat- 
ed with the large glycoprotein subunit of the purified receptor. In blots of nonreducing gels, a larger protein 
of M,- 170000 was seen and three of the antibodies recognised additional components at M,- 310000 and 
-330000. Crossreactive material of similar molecular mass was also seen in rabbit heart and brain, and 
in the skeletal muscle of other species. 
Dihydropyridine; Dihydropyridine receptor; Ca 2+ channel; Monoclonal antibody 
1. INTRODUCTION 
Due to their high-affinity binding, the 
1 ,Cdihydropyridine (DHP) Ca2+ channel an- 
tagonists have proved most useful as biochemical 
probes for the voltage-sensitive Ca” channel [ 1,2]. 
To date, most studies of the molecular properties 
of the DHP receptor have concentrated on the 
relatively abundant receptor of the skeletal muscle 
transverse tubule (T-tubule) membrane [3]. 
There is general agreement, both from purifica- 
tion [4-61 and affinity labelling studies [7,8], that 
a large glycoprotein of Mr 130000-150000 is im- 
plicated in the skeletal muscle DHP receptor struc- 
ture and several laboratories have provided 
evidence for additional components of M, 50000 
and 32000-36000 [4-7,9]. Subunit analysis of 
Correspondence address: R.I. Norman, Dept of 
Medicine, Clinical Sciences Building, Leicester Royal In- 
firmary, PO Box 65, Leicester LE2 7LX, England 
pharmacologically more interesting DHP receptors 
such as those from heart [lo] and smooth muscle 
has proved more difficult. 
Using monoclonal antibodies raised against the 
skeletal muscle DHP receptor from rabbit, we 
demonstrate in this report that antigenic deter- 
minants on the skeletal muscle DHP-sensitive Ca2+ 
channel are shared between putative Ca2+ channel 
components in various tissues and species. 
2. MATERIALS AND METHODS 
2.1. Membrane preparations 
Skeletal muscle microsomal membrane fractions 
were prepared according to Fosset et al. [3]. 
Microsomes from other tissues were prepared ac- 
cording to Glossmann and Ferry [l l] in 0.3 M 
sucrose, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 40 mM Mops, pH 7.5. T-tubule mem- 
branes were prepared from rabbit white skeletal 
muscle as described by Rosemblatt et al. [12]. 
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2.2. I,4_Dihydropyridine receptor purification 
Purification of the DHP receptor from T-tubule 
membranes was performed as described by Borsot- 
to et al. [4] in medium A (0.1% CHAPS, 5% 
glycerol, 0.02% phosphatidylcholine, 140 mM 
NaCl, 1 mM CaC12, 1 mM iodoacetamide, 
0.1 mM PMSF, 1 PM pepstatin A, 20 mM Tris, 
pH 7.5) with a modification following the gel 
filtration step. Ultrogel A2 fractions containing 
DHP receptor activity were pooled and adjusted to 
contain 1% Triton X-100. Following incubation at 
4°C for 15 min the mixture was applied to a 1.8 ml 
wheat germ agglutinin-Ultrogel (WGA-Ultrogel, 
LKB) column. The breakthrough was reapplied 
and the column washed sequentially with 10 ml 
medium A containing 0.1% Triton X-100 in place 
of CHAPS, 10 ml medium A containing 1% 
CHAPS and finally 5 ml medium A. The receptor 
was eluted with 200 mM N-acetyl-D-glucosamine 
in medium A. 
2.3. Preparation of monoclonal antibodies 
BALB/C mice were immunized by in- 
traperitoneal injections of extensively purified 
DHP receptor (0.8-l .O nmol [3H]PN 
200-l lo-binding sites per mg of protein; 10 pg pro- 
tein per animal) prepared as an alum precipitate, 
followed after 6 weeks by a similar amount of pro- 
tein injected in saline. 7 days before being killed 
one animal received about 5 /cg purified receptor in 
Freund’s incomplete adjuvant followed on each of 
the next 6 days by an intraperitoneal injection of a 
similar amount of receptor in saline. The spleen 
was excised 1 day later and the cells fused with 10’ 
NSO/l myeloma cells as described by Galfre and 
Milstein [13] except that 50% polyethylene glycol 
4000 (Merck, Cat. no.9727) was used. After selec- 
tion of hybridoma cells, positive clones were 
replated at limiting dilution to ensure the 
monoclonal nature of the cell lines. Ascitic fluids 
were produced by injecting about 10’ monoclonal 
hybridoma cells into pristane-primed BALB/C 
mice. 
2.4. Solid-phase antibody assay 
Microtitre plate wells were coated for 16 h at 
4°C with 50 ng of purified DHP receptor in 50~1 
of phosphate buffered saline (PBS; 50 mM sodium 
phosphate, pH 8.0,0.9% NaCl). The CHAPS con- 
centration in the diluted receptor was <0.003%. 
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Each well was washed for 1 h with 0.5% casein, 
10% calf serum in PBS. Wells were incubated for 
2 h at room temperature with the hybridoma 
supernatant being tested, then sequentially with 
50 ,ul of rabbit anti-mouse IgG (Miles; 1: 1000 dilu- 
tion) and goat anti-rabbit immunoglobulin cou- 
pled to peroxidase (Miles; 1: 1000 dilution) in 1% 
calf serum, 0.05% Tween 20, PBS, each for 1 h at 
room temperature. Positive wells were identified 
by the development of blue colouration following 
the application of 50~1 of 10 mg/ml 3,3’,5,5’- 
tetramethylbenzidine (Miles) in 0.1 M sodium 
acetate/citrate, pH 6.0, 0.0045% H202. Between 
steps, wells were washed three times with 0.05% 
Tween 20 in PBS. 
2.5. Immunoblots 
Samples of T-tubule (60 pg) or microsomal 
membranes (0.25-3 mg protein) were denatured in 
2% SDS, 9% glycerol, 75 mM Tris-HCl, pH 6.8, 
and either 0.6% dithiothreitol (disulphide reducing 
conditions) or 8 mM iodoacetamide (nonreducing 
conditions) and loaded on 4-12% linear 
polyacrylamide gradients according to Laemmli 
[14]. Following transfer of resolved proteins to 
nitrocellulose [ 151, the paper was incubated for 
16 h at 4°C with 1% bovine serum albumin, 0.5% 
casein, 0.05% Tween 20,0.9% NaCl, 10 mM Tris- 
HCI, pH 7.5. Antibody binding to nonreduced 
membrane components was assayed by incubating 
the nitrocellulose paper with diluted ascitic fluids 
(1: 500 in 0.05% Tween 20, 0.9% NaCI, 10 mM 
Tris, pH 7.5) for 2 h at room temperature followed 
by sequential incubations with rabbit anti-mouse 
IgG (1: 500 dilution, 1 h) and goat anti-rabbit IgG 
coupled to peroxidase (Miles; 1: 500 dilution, 2 h). 
For reduced membrane samples, the rabbit anti- 
mouse IgG incubation was followed by sequential 
incubations with swine anti-rabbit IgG (Dako- 
patts; 1:500 dilution, 1 h) and rabbit peroxidase 
anti-peroxidase complex (Dakopatts; 1: 500 dilu- 
tion, 1 h). Immunoblots were then developed using 
0.2 mg/ml diaminobenzidine (Sigma), 0.9% NaCl, 
20 mM Tris-HCl, pH 7.5, 0.003% HzOz. Between 
steps the nitrocellulose paper was washed for 
10 min in 0.25% sodium lauryl sarcosine, 0.25% 
Nonidet P-40, 1 M NaCl, 10 mM Tris-HCI, pH 
7.5. 
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3. RESULTS AND DISCUSSION 
The spleen of a hyperimmune BALB/C mouse 
was removed and monoclonal antibody producing 
hybridoma cells isolated as described in section 2. 
Cell supernatant from monoclonal cell lines was 
assayed in the solid-phase assay against extensively 
purified DHP receptor (0.8-l .O nmol (+)- 
t3H]PN 200-llO-binding sites per mg of protein). 
From the receptor molecular size of Mr -210000 
determined by radiation inactivation [16] and 
assuming one DHP binding site per receptor 
molecule, the specific activity of a homogeneous 
preparation would be 4.76 nmol/mg. The 
minimum purity of the preparations used for assay 
was estimated at 17% but it is likely that the degree 
of purity was substantially underestimated as a 
result of activity loss due to the half-life of the 
DHP receptor in CHAPS solution [17] and to the 
high detergent concentrations used during the 
WGA-Ultrogel purification step [4]. When ana- 
lysed by SDS-polyacrylamide gel electrophoresis 
under reducing conditions, these receptor prepara- 
tions consisted of a major component of M, 
-140000 with minor bands at A4, -100000 and 
33000 (not shown). Out of 360 hybridoma super- 
natants tested, 33 were positive in the solid-phase 
assay against this extensively purified DHP recep- 
tor and 31 individual clones were isolated by 
plating at limiting dilution. 
Both purification [4-61 and affinity labelling 
studies [7,8] have identified a polypeptide chain of 
A4,140000 as a component of the DHP receptor of 
the skeletal muscle voltage-sensitive Ca2+ channel. 
Four antibodies ((uDHP-R 11, 13, 14 and 15), out 
of the panel of 3 1, produced detectable reaction on 
immunoblots of skeletal muscle T-tubule mem- 
branes. Under reducing conditions all four an- 
II 
1 2 3 4 g 
Fig. 1. Immunoblots of rabbit skeletal muscle transverse tubule membranes after electrophoresis under reducing (A) and 
nonreducing conditions (B). Lanes: 1, CYDHP-R 11; 2, CYDHP-R 13; 3, wDHP-R 14; 4, cyDHP-R 15; 5, anti-gyrase B 
control ascitic fluid (Harrison, T.M., unpublished). M, markers are from Sigma: myosin (200000), fl-galactosidase 
(116000), phosphorylase b (97000), bovine serum albumin (66000), ovalbumin (45000), pepsin (35000), carbonic 
anhydrase (29000) and trypsinogen (24000). 
129 
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tibodies bound specifically to a single polypeptide 
of A!& -140000 (fig.lA). This polypeptide co- 
migrated with the 140 kDa polypeptide present in 
the extensively purified DHP receptor prepara- 
tions (not shown) indicating that these monoclonal 
antibodies detect specifically the large component 
of the Ca*+ channel protein. 
Under nonreducing conditions the four an- 
tibodies detected larger protein bands (fig.lB). All 
four recognized a protein of M, 165000-170000 
and cuDHP-Rs 13, 14 and 15 detected two larger 
proteins of M, 310000 and 330000. It has been sug- 
gested that the transition between M, 170000 and 
M, 140000 on disulphide reduction is due to the 
release of a small disulphide linked component of 
M -32000 [9]. Specific labelling of a 140 kDa 
polypeptide could not be detected under nonreduc- 
ing conditions. A diffuse region of nonspecific 
staining in the 130-140 kDa region was also pre- 
sent in the control track of nonreduced material in 
which the (YDHP-R antibody was replaced by a 
monoclonal anti-bacterial Gyrase B (see fig.lB). It 
is possible that this region of nonspecific staining, 
which has been observed previously in immunoblot 
studies on rabbit skeletal muscle membranes [9], 
A 
1234547B 
was due to endogenous immunoglobulin molecules 
associated with the membrane preparation. 
The observation of specific anti-DHP receptor 
antibody binding to large protein bands of M, 
> 300000 indicates that additional polypeptides 
may be required for the complete native structure 
of the DHP-receptor Ca*’ channel protein. 
Although there are no indications of their identity 
in this study, possible polypeptide candidates of M, 
50000-55000 and -99000 have been implicated in 
other studies of the DHP receptor protein [6,7]. 
Possible immunochemical similarities between 
putative DHP-sensitive Ca*+ channels in different 
species and tissues were investigated by im- 
munoblot assay using ~uDHP-R 13. Im- 
munocrossreactivity was detected between the 
rabbit skeletal muscle DHP receptor and a compo- 
nent in skeletal muscle microsome preparations 
from mouse, rat and frog. In each case a single 
polypeptide of iWr 140000- 145 000 was detected by 
crDHP-R 13 under reducing conditions (fig.2A), 
whereas under nonreducing conditions the an- 
tibody identified a protein of A4, 170000-180000 
(fig.2B). Although not observed in frog 
microsomes, a large component of MI -310000 
8 
Fig.2. Immunoblots of skeletal muscle microsomes after electrophoresis under reducing (A) and nonreducing conditions 
(B). Lanes: 1 and 2, rabbit (0.25 mg); 3 and 4, rat (0.75 mg); 5 and 6, mouse (0.3 mg); 7 and 8, frog (0.33 mg). Lanes 
1, 3, 5 and 7 with ~uDHP-R 13, lanes 2, 4, 6 and 8 with anti-gyrase B control ascitic fluid. MI markers as in fig.1. 
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Fig.3. Immunoblots of brain, heart and liver 
microsomes after electrophoresis under reducing 
conditions. Lanes: 1 and 2, brain (3.0 mg); 3 and 4, 
heart (1.85 mg); 5 and 6, liver (3.0 mg). Lanes 1, 3 and 
5 with aDHP-R 13, lanes 2, 4 and 6 with anti-gyrase B 
control ascitic fluid. M, markers as in fig. 1. 
was recognised by (uDHP-R 13 in both mouse and 
rat preparations as well as rabbit under nonreduc- 
ing conditions. This similarity in reduc- 
ing/nonreducing immunoblot profiles indicates 
that, although minor differences in subunit 
molecular mass exist (fig.2 and [5]), the structure 
of the skeletal muscle DHP receptor is very similar 
in each of the species investigated. As with the im- 
munoblots of rabbit T-tubule membranes (fig. 1) a 
diffuse region of nonspecific staining was present 
under nonreducing conditions on blots of all three 
mammalian microsomal preparations but absent 
from those of frog (see fig.2B). Due to this 
nonspecific staining, the presence of specific stain- 
ing at M, 170000 in mouse and rat samples was not 
as clearly identified as in rabbit and frog samples. 
In these cases specific staining appeared as darker 
and broader bands in the 170 kDa region com- 
pared to control tracks (fig.lB). 
Immunocrossreactivity between the rabbit 
skeletal muscle DHP receptor and microsomal 
components from a number of other rabbit tissues 
was also investigated. Heart and brain microsomes 
both contained a component of Mr -140000 under 
reducing conditions which was recognised 
specifically by CYDHP-R 13 (fig.3). It is noteworthy 
that in these two tissues the presence of DHP- 
sensitive Ca’+ channels has been established by ex- 
tensive ligand binding studies [ 1,2]. We were 
unable to detect this component in any other tissue 
examined, including liver (fig.3), kidney, lung and 
small intestine, which is not surprising in view of 
the low levels of specific DHP binding which have 
been reported in these cases [2]. 
In conclusion, this work provides evidence that 
the structures of the voltage-sensitive Ca2+ channel 
DHP receptors, both in different species and in 
different tissues, are immunologically related. Our 
results are consistent with the hypothesis that the 
large 140 kDa polypeptide of the native DHP 
receptor is disulphide linked to a second small 
polypeptide component [9]. Furthermore, data ob- 
tained under nonreducing conditions indicate that 
additional components of the Ca2’ channel protein 
remain to be resolved unequivocably. 
The series of monoclonal antibodies described in 
this paper will provide useful tools, not only for 
future immunological studies of the DHP-sensitive 
Ca2+ channel but also in purification studies of 
pharmacologically important Ca2+ channels from 
heart and smooth muscle and for the isolation of 
Ca2+ channel cDNA for primary sequence deter- 
mination. 
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